Emergent BioSolutions (EBS) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 11.6% versus a loss of 28.7%. Over five years, ENTA leads with a -82.7% price change compared with -86.1% for EBS. Emergent BioSolutions is the larger company by market cap ($362.5 million vs $360.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | ENTA |
|---|---|---|
| Share price | $7.07 | $12.37 |
| Market cap | $362.50M | $360.28M |
| 1-day change | +1.73% | +1.64% |
| YTD return | -42.80% | -21.56% |
| 1-year return | -28.73% | +11.64% |
| 5-year return | -86.05% | -82.69% |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.40 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $17.15 |
| 52-week low | $4.36 | $10.20 |
| Distance from 52-week high | -49.72% | -27.87% |
| Average volume | 1.16M | 227.13K |
| Shares outstanding | 51.27M | 29.13M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed EBS by 40.4 percentage points over the past year.
EBS vs ENTA FAQ
Which is bigger, Emergent BioSolutions or Enanta Pharmaceuticals?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $362.50M compared with $360.28M for Enanta Pharmaceuticals (ENTA).
Which stock has performed better over the past year, EBS or ENTA?
ENTA returned +11.64% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Enanta Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.